These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 29675019)
1. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome. Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M Front Immunol; 2018; 9():568. PubMed ID: 29675019 [TBL] [Abstract][Full Text] [Related]
2. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755 [TBL] [Abstract][Full Text] [Related]
9. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome. Cohen JI Front Immunol; 2018; 9():237. PubMed ID: 29599765 [TBL] [Abstract][Full Text] [Related]
10. Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Wentink M; Dalm V; Lankester AC; van Schouwenburg PA; Schölvinck L; Kalina T; Zachova R; Sediva A; Lambeck A; Pico-Knijnenburg I; van Dongen JJ; Pac M; Bernatowska E; van Hagen M; Driessen G; van der Burg M Clin Immunol; 2017 Mar; 176():77-86. PubMed ID: 28104464 [TBL] [Abstract][Full Text] [Related]
11. A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects. Bildik HN; Esenboga S; Halaclı SO; Karaatmaca B; Aytekin ES; Nabiyeva N; Akarsu A; Ocak M; Erman B; Tan C; Arikoglu T; Yaz I; Cicek B; Tezcan I; Cagdas D Pediatr Allergy Immunol; 2024 Sep; 35(9):e14245. PubMed ID: 39312287 [TBL] [Abstract][Full Text] [Related]
12. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review. Yang X; Xi R; Bai J; Pan Y Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229 [TBL] [Abstract][Full Text] [Related]
13. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature. Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802 [TBL] [Abstract][Full Text] [Related]
14. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes. Redenbaugh V; Coulter T Front Pediatr; 2021; 9():702872. PubMed ID: 34422726 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome. Del Pino-Molina L; Torres Canizales JM; Rodríguez-Pena R; López-Granados E Cytometry B Clin Cytom; 2021 Jul; 100(4):460-466. PubMed ID: 32961022 [TBL] [Abstract][Full Text] [Related]
16. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome. Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059 [TBL] [Abstract][Full Text] [Related]
18. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature. Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393 [TBL] [Abstract][Full Text] [Related]
19. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962 [TBL] [Abstract][Full Text] [Related]
20. Systematic review of mortality and survival rates for APDS. Hanson J; Bonnen PE Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]